Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
JAMA Oncology|November 4, 2021
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic StudiesSamantha Brown, Jessica A Lavery, Ronglai Shen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2020
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung CancerAdam J Schoenfeld, Joseph M Chan, Daisuke Kubota, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C Osorio, Kathryn C Arbour, Dung T Le, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.JAMA Oncology|May 29, 2020
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label TrialHelena A Yu, Adam J Schoenfeld, Alex Makhnin, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.Pageof 6